The role of 18F-FDG PET/CT in diagnosis and treatment evaluation for ocular adnexal mucosa-associated lymphoid tissue lymphoma

Abstract

Objective: The purpose of this study is to evaluate the value of fluorine-18-fludeoxyglucose positron emission tomography (18F-FDG PET)/CT in the diagnosis and treatment evaluation of ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma. Methods: 70 patients with OAML who received radiotherapy were recruited in our study. All the patients had the 18F-FDG PET/CT examination before the treatment. We retrospectively reviewed the medical records, pathological reports, laboratory results, and imaging features of all patients. The associations between 18F-FDG PET/CT parameters and Epstein-Barr virus antibodies, treatment response, MRI data, and Ki-67 expression were investigated. Results: The PET/CT scan indicated that 80% (56/70) of the patients showed orbital FDG avidity. The median level of maximum standardized uptake value (SUVmax) of the lesions was 4.65 ± 3.00 (range:1.2–13.5). 92.0% (46/50) of the mass-forming lesions showed 18F-FDG avidity, while only 50.0% (10/20) of the non-massive lesions had 18F-FDG avidity (χ2 = 13.23, p=0.01). The SUVmax in orbit, conjunctiva, and lacrimal gland lymphoma were 5.6, 2.9, and 3.7, respectively. A significant difference was identified of SUVmax among the three locations’ lymphoma using one-way ANOVA analysis (F = 5.039, p = 0.01). After completion of radiotherapy, the complete remission rate was achieved in 30.8% (4/13) of the patients without 18F-FDG avidity, and 70.4% (38/54) in cases with 18F-FDG avidity (χ2 = 5.43, p = 0.02). The correlation between high Ki-67 score and 18F-FDG avidity was confirmed (χ2 = 3.916, p = 0.048); however, no significant correlation was found between the SUVmax and Ki-67 score of the lesions (p = 0.971). Three patients (3/70, 4.3%) were upregulated the stage via PET/CT. Conclusion: 18F-FDG PET/CT had some potential values in the diagnosis and assessment of treatment response in patients with OAML. Advances in knowledge: The value of 18F-FDG PET/CT for patients with OAML.

MRI-based long-term follow-up of indolent orbital lymphomas after curative radiotherapy: imaging remission criteria and volumetric regression kinetics

“…In irradiated orbital lymphomas high but varying rates of CR (range: 52-100%) are reported 1,[4][5][6][7][12][13][14][15][16][17][18]20 . Due to the fact of missing follow-up standardization some authors do not provide information on the radiological follow-up procedures 4,12,13 whereas in one publication radiological follow-up was only performed if appropriate 1 .…”

“…Due to the fact of missing follow-up standardization some authors do not provide information on the radiological follow-up procedures 4,12,13 whereas in one publication radiological follow-up was only performed if appropriate 1 . Some data exists on patients receiving routine radiological follow-up procedures, however CT scans were solely or CT and MRI scans were equally performed in these studies [5][6][7]14,15,17,18,20 . Furthermore, the before mentioned studies do not differentiate between orbital and conjunctival lesion 1,[4][5][6][7][12][13][14][15][16][17][18]20 .…”

“…Some data exists on patients receiving routine radiological follow-up procedures, however CT scans were solely or CT and MRI scans were equally performed in these studies [5][6][7]14,15,17,18,20 . Furthermore, the before mentioned studies do not differentiate between orbital and conjunctival lesion 1,[4][5][6][7][12][13][14][15][16][17][18]20 .…”

“…In case of residual disease, one differentiates between partial response (PR) or stable disease according to the shrinkage degree of the cross product of largest tumor diameter and the shortest axis perpendicular diameter 11 . In orbital lymphomas high but varying rates of CR are reported after irradiation (range: 52-100%) with 5-years PFS rates ranging from 75 to 100% 1,[3][4][5][6][7]9,[12][13][14][15][16][17][18][19][20] . However, no standardized follow-up protocol exists and the information on the applied follow-up procedures is often sparse 1,4,12,13 .…”

Non‑Hodgkin's lymphomas of the lacrimal sac: Current insights and future directions (Review)

“…Advanced imaging techniques, such as fluorine-18-fludeoxyglucose PET-CT and diffusion-weighted imaging, exhibit potential in improving diagnostic accuracy through acquiring functional and metabolic information. PET-CT imaging also aids in treatment response assessment and disease recurrence detection ( 51 ). Notably, interpreting imaging findings in lacrimal sac NHL requires expertise and collaboration among clinicians to ensure accurate diagnosis and optimal patient care.…”